ES2150916T3 - Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados. - Google Patents

Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.

Info

Publication number
ES2150916T3
ES2150916T3 ES92917956T ES92917956T ES2150916T3 ES 2150916 T3 ES2150916 T3 ES 2150916T3 ES 92917956 T ES92917956 T ES 92917956T ES 92917956 T ES92917956 T ES 92917956T ES 2150916 T3 ES2150916 T3 ES 2150916T3
Authority
ES
Spain
Prior art keywords
gentisilic
proteins
alcohol
acid
radio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917956T
Other languages
English (en)
Inventor
Edward A Deutsch
Wilhelmus Theodorus Goedemans
Jong Martinus Theodorus De
Kathleen M Miller
James W Brodack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Application granted granted Critical
Publication of ES2150916T3 publication Critical patent/ES2150916T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

EL ACIDO GENTISICO Y SUS DERIVADOS INHIBEN SUSTANCIALMENTE LA AUTORRADIOLISIS DE PEPTIDOS. EL ACIDO GENTISICO O SUS DERIVADOS SE PUEDEN UTILIZAR TAMBIEN JUNTO CON OTROS ESTABILIZADORES TALES COMO INOSITOL, ACIDO ASCORBICO O CITRATO PARA INHIBIR LA AUTORRADIOLISIS DE PEPTIDOS RADIOETIQUETADOS.
ES92917956T 1991-08-29 1992-07-31 Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados. Expired - Lifetime ES2150916T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75182591A 1991-08-29 1991-08-29

Publications (1)

Publication Number Publication Date
ES2150916T3 true ES2150916T3 (es) 2000-12-16

Family

ID=25023648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917956T Expired - Lifetime ES2150916T3 (es) 1991-08-29 1992-07-31 Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.

Country Status (11)

Country Link
US (1) US5384113A (es)
EP (1) EP0600992B1 (es)
JP (1) JP3853354B2 (es)
AT (1) ATE196428T1 (es)
AU (1) AU2462592A (es)
CA (1) CA2113995C (es)
DE (1) DE69231469T2 (es)
DK (1) DK0600992T3 (es)
ES (1) ES2150916T3 (es)
GR (1) GR3035067T3 (es)
WO (1) WO1993004702A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
GB9004017D0 (en) * 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilization of pharmacologically active compounds in delayed release agents.
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US20010055563A1 (en) 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997033580A1 (en) * 1996-03-11 1997-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6027710A (en) * 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
US6468971B1 (en) 1997-03-05 2002-10-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
AU1096000A (en) * 1998-09-25 2000-04-17 Mallinckrodt, Inc. Somatostatin receptor radioligand with increased uptake
CZ20014603A3 (cs) * 1999-06-29 2002-11-13 Mallinckrodt Inc. Pouľití aminopolykarboxylátových ligandů při značení biologicky aktivních substrátů Tc-99m-trikarbonylovými prekurzory
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6881396B2 (en) * 2000-10-24 2005-04-19 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
US6902718B2 (en) * 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
JP2004529884A (ja) * 2001-02-26 2004-09-30 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 金属放射性医薬のためのアスコルビン酸類似体
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
ES2347535T3 (es) 2002-11-05 2010-11-02 Ion Beam Applications S.A. Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol.
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
CA2526556C (en) * 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
CA2610252A1 (en) * 2005-06-14 2006-12-21 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
GB0514087D0 (en) 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
RU2474435C2 (ru) * 2007-11-07 2013-02-10 Джи-И Хелткер БВ Стабилизация радиофармацевтических композиций
EP2234636A4 (en) * 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
AU2009220244B2 (en) 2008-02-29 2014-10-09 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
KR101602992B1 (ko) * 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
CN102858752B (zh) 2010-02-08 2018-10-16 兰休斯医疗成像公司 用于合成显像剂和其中间体的方法和装置
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
HUE071169T2 (hu) 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
AU2017354941B2 (en) * 2016-11-04 2021-02-11 Clarity Pharmaceuticals Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
TW202517302A (zh) 2018-07-25 2025-05-01 法商高級催化劑應用品有限公司 穩定的、濃縮的放射性核種錯合物溶液
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
JP2025529820A (ja) * 2022-08-16 2025-09-09 クラリティ・ファーマシューティカルズ・リミテッド 放射線療法および画像診断のための製剤ならびに疾患の処置、診断および画像化におけるその使用
CN121532218A (zh) 2023-06-16 2026-02-13 普罗热尼奇制药公司 前列腺特异性膜抗原（psma）放射性标记抑制剂[18f]dcfpyl的改进的合成
US12514939B2 (en) * 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof
WO2026008525A1 (en) 2024-07-01 2026-01-08 Bayer Aktiengesellschaft Stable radionuclide-containing formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497744A (en) * 1978-03-31 1985-02-05 Mallinckrodt, Inc. Gentisic acid salts as radiographic scanning agent stabilizers
US4229427A (en) * 1978-06-28 1980-10-21 The Procter & Gamble Company Radioactive scanning agents with hydroquinone stabilizer
US4232000A (en) * 1978-06-28 1980-11-04 The Procter & Gamble Company Radioactive scanning agents with stabilizer
US4232284A (en) * 1979-05-07 1980-11-04 Power Parts, Inc. Ignition coil and electrical connector therefor
US4504463A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4440738A (en) * 1982-06-10 1984-04-03 Mallinckrodt, Inc. Stable radiographic imaging agents
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US4510125A (en) * 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS59199636A (ja) * 1983-04-26 1984-11-12 Nippon Mejifuijitsukusu Kk 放射性診断剤
US4942231A (en) * 1984-05-24 1990-07-17 Mallinckrodt, Inc. Method of preparing a chlorinated, brominated, radio-brominated, iodinated and/or radioiodinated aromatic or heteroaromatic compound
EP0313712B1 (de) * 1987-10-30 1992-07-29 SORIN BIOMEDICA S.p.A. Stabile radiodiagnostische Präparate und ihre Herstellung
GB2239178B (en) * 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats

Also Published As

Publication number Publication date
EP0600992B1 (en) 2000-09-20
JP3853354B2 (ja) 2006-12-06
EP0600992A1 (en) 1994-06-15
CA2113995A1 (en) 1993-03-18
JPH06510539A (ja) 1994-11-24
DE69231469D1 (de) 2000-10-26
ATE196428T1 (de) 2000-10-15
DE69231469T2 (de) 2001-01-25
DK0600992T3 (da) 2000-10-09
CA2113995C (en) 2003-04-22
WO1993004702A1 (en) 1993-03-18
US5384113A (en) 1995-01-24
GR3035067T3 (en) 2001-03-30
AU2462592A (en) 1993-04-05

Similar Documents

Publication Publication Date Title
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ES2061632T3 (es) Kluyveromyces como celula hospedante.
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
DK0720482T3 (da) Prosaposin og cytokin-afledte peptider som terapeutiske midler
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
FI101720B1 (fi) Synteettisen DNA:n konstruointi ja sen käyttö suurten polypeptidien synteesissä
ES8703490A1 (es) Un procedimiento para producir un polipeptido que tiene o contiene un polipeptido de factor de necrosis de tumor humano
ATE81135T1 (de) Aktive thymopentin-analoga.
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
KR840001836A (ko) 생리활성 물질의 제법
ES2058486T3 (es) Inmunogenos nativos y recombinantes del grupo b de eimeria tenella utiles como vacunas para las coccidiosis.
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
ES2006476A6 (es) Un procedimiento para obtener interleukin-2 humana
ES2062982T3 (es) Clonaje y expresion del factor de crecimiento de fibroblasto acido.
ATE110742T1 (de) Peptid-verbindungen.
AR023481A1 (es) Vectores que contienen un gen que codifica cd40 y/o cd40l bajo el control de un promotor citoquina-inducible, metodos para su produccion y usos de losmismos
AR013618A1 (es) Metodo y composiciones para la distribucion y expresion de acidos nucleicos de interferon
AR241800A1 (es) Procedimiento para preparar compuestos de eglina y procedimiento para obtener preparados farmaceuticos que incluyan a dichos compuestos de eglina como agente activo.
ES2061218T3 (es) Composiciones farmaceuticas estabilizadas.
DE69027466D1 (de) Achromobacter-Protease-I-Gen sowie Genprodukt
ES8802441A1 (es) Procedimiento para preparar laminina humana
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600992

Country of ref document: ES